523 related articles for article (PubMed ID: 6425010)
1. The short-term effects of a low-dose oral contraceptive on glucose metabolism, plasma lipids and blood clotting factors.
Skouby SO; Wagner HH; Andersen O
Contraception; 1983 Nov; 28(5):489-99. PubMed ID: 6425010
[TBL] [Abstract][Full Text] [Related]
2. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
3. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a new triphasic oral contraceptive in private practice.
Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
[TBL] [Abstract][Full Text] [Related]
5. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
Prasad RN; Liew D; Ratnam SS
Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
[TBL] [Abstract][Full Text] [Related]
6. Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel.
Fioretti P; Fruzzetti F; Navalesi R; Ricci C; Miccoli R; Cerri M; Orlandi MC; Melis GB
Contraception; 1987 Mar; 35(3):229-43. PubMed ID: 2956055
[TBL] [Abstract][Full Text] [Related]
7. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
Godsland IF; Crook D; Devenport M; Wynn V
Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
[TBL] [Abstract][Full Text] [Related]
8. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
9. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
10. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
[TBL] [Abstract][Full Text] [Related]
11. Plasma lipoproteins and fatty acid composition after "minipill".
Sassolas A; Lagarde M; Guichardant M; Quincy C; Dechavanne M
Contraception; 1983 Oct; 28(4):357-68. PubMed ID: 6421540
[TBL] [Abstract][Full Text] [Related]
12. Plasma glucose and insulin levels in women using a levonorgestrel-containing triphasic oral contraceptive for three months.
Spellacy WN; Ellingson AB; Kotlik A; Tsibris JC
Contraception; 1988 Jul; 38(1):27-35. PubMed ID: 3139358
[TBL] [Abstract][Full Text] [Related]
13. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
14. Two oral contraceptives, efficacy, serum proteins, and lipid metabolism. A comparative multicentre study on a triphasic and a fixed dose combination.
Cullberg G; Samsioe G; Andersen RF; Bredesgaard P; Andersen NB; Ernerot H; Fanøe E; Fylling P; Haack-Sørensen PE; Klottrup P; Pedersen JH; Sandager T
Contraception; 1982 Sep; 26(3):229-43. PubMed ID: 6217028
[TBL] [Abstract][Full Text] [Related]
15. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
16. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen.
Wilson ES; Cruickshank J; McMaster M; Weir RJ
Br J Obstet Gynaecol; 1984 Dec; 91(12):1254-60. PubMed ID: 6440589
[TBL] [Abstract][Full Text] [Related]
17. Lipid and biochemical changes after low-dose oral contraception.
Loke DF; Ng CS; Holck S; Hall PE; Ratnam SS
Contraception; 1992 Sep; 46(3):227-41. PubMed ID: 1451519
[TBL] [Abstract][Full Text] [Related]
18. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
[TBL] [Abstract][Full Text] [Related]
19. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
[TBL] [Abstract][Full Text] [Related]
20. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]